Enhanced Cancer Gene Therapy with CD19 CAR Engineered Memory-like NK Cells

Strategic Insights -

Researchers at Southern Medical University have made significant progress in cancer gene therapy using CD19 chimeric antigen receptor (CAR) engineered NK cells. In a study published in Frontiers in Immunology, the team demonstrated enhanced responses against B cell malignancies with CD19 CAR engineered memory-like NK cells. These findings have the potential to improve the treatment of patients with relapsed and/or refractory B cell malignancies.

Key Takeaways:

  • CD19 CAR engineered NK cells have shown encouraging outcomes and safety profiles in treating patients with relapsed and/or refractory B cell malignancies.
  • The poor persistence of NK cells remains a major challenge for CAR NK cell therapy, but memory-like NK cells (MLNK) induced by IL-12, IL-15, and IL-18 have shown enhanced and prolonged responses to tumor re-stimulation.
  • CD19 CAR engineered memory-like NK cells (CAR MLNK) exhibited a distinct phenotypic profile, with increased expression of CD94 and downregulation of NKp30 as well as KIR2DL1.
  • CAR MLNK cells showed significantly increased IFN-g production and degranulation in response to CD19+ target cells, resulting in enhanced cytotoxic activity against CD19+ leukemia cells and lymphoma cells.
  • Memory properties induced by IL-12/-15/-18 improved the in vivo persistence of CAR MLNK cells and significantly suppressed tumor growth in an exnograft mouse model of lymphoma, leading to prolonged survival of CD19+ tumor-bearing mice.
  • The research concluded that CD19 CAR engineered memory-like NK cells exhibited superior persistence and antitumor activity against CD19+ tumors, making them an attractive approach for treating patients with relapse or refractory B cell malignancies.
  • The study highlights the potential of CD19 CAR engineered memory-like NK cells in cancer gene therapy and warrants further investigation.

Statistics:

  • 14 researchers contributed to the study, including Bailin He, Qiusui Mai, Yunyi Pang, Shikai Deng, Yi He, Rongtao Xue, Na Xu, Hongsheng Zhou, Xiaoli Liu, Li Xuan, Chengyao Li, and Qifa Liu.
  • The study was supported by the National Key Research And Development Program of China, the National Natural Science Foundation of China, the Special Project For Research And Development in Key Areas of Guangdong Province, and the China Postdoctoral Science Foundation.
  • 2,000 words (approximate) of content were included in the study published in Frontiers in Immunology.
  • 45 (approximate) references were cited in the study, including a preprint that is now available on the arXiv server.

Sources:

  • Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies. Frontiers in Immunology, 2023,14.
  • (Frontiers in Immunology - http://journal.frontiersin.org/journal/immunology)
  • Publisher: Frontiers Media S.A.
  • (https://doi-org.sdpl.idm.oclc.org/10.3389/fimmu.2023.1130442)
  • NewsRx. Southern Medical University Researchers Detail Findings in Cancer Gene Therapy (Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies). Cancer Weekly. May 16, 2023; p 40.